Kimberly-Clark Offers EU Remedies to Clear $40B Kenvue Deal
KMB is trading near its 52-week low of $92.42 (7.1% above the low).
Summary
Kimberly-Clark has submitted remedies to the European Commission to address antitrust concerns over its $40 billion acquisition of Kenvue. The EU extended its decision deadline to October 13 from September 29, signaling that the concessions are being taken seriously. This follows conditional approvals from Australia and South Africa, and a Reuters report last week that asset sales were likely. The remedies are not detailed, but the extension suggests the EU may accept them without a full investigation. A phase 1 approval would remove a major regulatory hurdle and keep the deal on track for completion.
At the time of this announcement, KMB was trading at $99.01 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $32.9B. The 52-week trading range was $92.42 to $125.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.